ReportWire

Tag: substance

  • Central Florida doctor unveils kratom research findings, potential dangers

    [ad_1]

    Central Florida doctor unveils kratom research findings, potential dangers

    Orlando Health Orlando Regional Medical Center emergency medicine physician and toxicologist, Dr. Josef Thundiyil, joins WESH 2 to discuss the potential dangers of kratom.

    ALERT AND FOCUSING ON A SUBSTANCE CALLED KRATOM. ACCORDING TO THE U.S. FOOD AND DRUG ADMINISTRATION, THE FDA HERE SAYS THIS SUPPLEMENT IS TYPICALLY MARKETED AS AN ENERGY BOOSTER, MOOD LIFTER, PAIN RELIEVER, AND OPIOID WITHDRAWAL REMEDY. IT’S FOUND AT DISPENSARIES, EVEN RESTAURANTS, SOMETIMES INFUSED WITH DRINKS. AND DESPITE ITS GROWING POPULARITY, THERE ARE MANY QUESTIONS WHEN IT COMES TO THE SUBSTANCE. SO HERE TO GIVE US ANSWERS AND SHARE RESEARCH AND FINDINGS, WE HAVE EMERGENCY MEDICINE PHYSICIAN AND TOXICOLOGIST AT ORLANDO REGIONAL MEDICAL CENTER, DOCTOR JOSEPH DUNHILL. GREAT TO SEE YOU, DOCTOR. THANK YOU FOR HAVING ME. OKAY, SO YOU’VE DONE THE WORK HERE. THIS IS SOMETHING THAT WE’VE HEARD A GOOD BIT ABOUT LATELY. THE KRATOM PRODUCTS. WHAT ARE YOUR FINDINGS IN TERMS OF LOOKING INTO THIS SUBSTANCE THAT IS REALLY WIDELY POPULAR AND WIDELY AVAILABLE? YEAH. AS A BACKGROUND, THERE’S A FEW CONCERNS THAT HAVE COME UP. NUMBER ONE, IT’S VERY UNREGULATED. THERE’S ABOUT 40 DIFFERENT CHEMICAL ALKALOIDS IN THIS. THE SECOND IS THAT WE KNOW IT’S ADDICTIVE. SOME OF THE REPORTS FROM PEOPLE IS THAT IT’S COMPULSIVELY ADDICTIVE. PEOPLE SPENDING HUNDREDS OF DOLLARS A DAY TO GET SORT OF A FIX WITH IT. THE OTHER THING WE KNOW IS THAT IT INTERACTS WITH EXISTING MEDICATIONS THAT MANY PEOPLE ARE ON. WE DON’T KNOW EXACTLY WHAT THOSE INTERACTIONS ARE. AND THEN THE FINAL THING, EVEN BEFORE I GOT INTO THIS RESEARCH, IS THAT WE KNOW THAT THERE’S NO PROVEN MEDICAL BENEFITS. SO PEOPLE ARE USING THIS WITH THE THOUGHT IT MIGHT BE HELPING, BUT WE DON’T KNOW THAT IT’S HELPING THEM WITH ANYTHING. AND YOU WORKED WITH A LOT OF MEDICAL PROFESSIONALS TO PUT THIS TOGETHER. MORE THAN TWO DOZEN, I BELIEVE. YEAH. WE WORKED ACTUALLY. IT WAS A GROUP OF US PHYSICIANS. WE ESSENTIALLY REACHED OUT TO 25 MEDICAL EXAMINERS IN THE STATE OF FLORIDA. REALLY TO TRY TO ANSWER THE QUESTION IS, ARE PEOPLE DYING FROM KRATOM? AND WE FOUND SOME VERY INTERESTING THINGS. WE ACTUALLY HAD THE MEDICAL EXAMINER SEND US ANY REPORTED DEATHS, AND WE FOUND ALMOST 40 DEATHS IN THE STATE OF FLORIDA OVER A PERIOD OF ABOUT FIVE YEARS. OKAY. AND WAS THIS TIED TO ANYTHING SPECIFIC? THE SUBSTANCE AND OPIOIDS OR ANYTHING ALONG THOSE LINES? NO, THESE ARE DEATHS IN THE ABSENCE OF OPIOIDS. NOW, WE KNOW THAT THE CHEMICAL STRUCTURE RESEMBLES OPIOIDS. AND THAT’S WHAT GAVE US THIS CONCERN THAT IT COULD CAUSE DEATH. AND WE STILL ARE LEFT WITH NOT KNOWING EXACTLY WHY SOME PEOPLE DIE AND SOME PEOPLE DON’T. BUT THE BOTTOM LINE IS IT STILL HAS SOME SIGNIFICANT DANGERS WITH IT. RIGHT. AND, YOU KNOW, AS A PHYSICIAN, YOU KNOW, WHAT IS YOUR ADVICE TO SOMEONE WHO’S, YOU KNOW, THERE’S SOMETHING THAT MAY CAUSE SOMETHING AS SEVERE AS DEATH? WHAT WHAT ARE YOU ADVISING PEOPLE? I WOULD ADVISE TREMENDOUS CAUTION. IT IS UNREGULATED. MOST OF THESE PRODUCTS DON’T HAVE ANY DOSING LISTED ON IT. WE KNOW IT INTERACTS WITH MEDICATIONS. YOU KNOW, MY TYPICAL ADVICE WOULD BE TALK TO YOUR PHYSICIAN ABOUT IT. BUT WHAT I’M FINDING IN THE COMMUNITY IS THIS THERE’S ENOUGH UNKNOWNS ABOUT THE SUBSTANCE THAT EVEN YOUR PHYSICIAN MAY NOT KNOW WHAT ALL THE INTERACTIONS WITH OTHER SUBSTANCES ARE. SO MAKE SURE YOU KNOW WHAT THEY ARE. AND AT THE MOMENT, I PERSONALLY WOULD ADVOCATE FOR SAFETY. BE VERY, VERY CAREFUL WITH THIS BECAUSE WE KNOW THERE IS HARM. WE KNOW THERE’S ADDICTION. ANYTIME THERE’S A POTENTIAL FOR ADDICTION AND ESCALATING USE, WE NOW KNOW THAT IT CAN ALSO CAUSE DEATH. YEAH. WHAT ARE THE MOST VULNERABLE POPULATIONS YOU’RE SEEING WHEN IT COMES TO THE SUBSTANCE? YEAH. FROM A PUBLIC HEALTH STANDPOINT, WE ALWAYS THINK ABOUT VULNERABLE POPULATIONS IN TERMS OF WHO MIGHT BE AT RISK. SO PEOPLE WHO ALREADY SUFFER FROM ADDICTION BECAUSE THEY MAY BE LOOKING FOR ANYTHING TO HELP THEM GET OFF OF SUBSTANCE USE. I ALWAYS AM CONCERNED ABOUT ADOLESCENTS AND YOUNG ADULTS. FOR THIS REASON, PEOPLE WHO ARE ON OTHER MEDICATIONS BECAUSE OF THE POTENTIAL TO INTERACT. AND SO THAT INCLUDES NOT ONLY YOUNG PEOPLE WHO ARE ON MEDICINES, BUT ESPECIALLY PEOPLE WHO ARE OLDER AND THE ELDERLY. THOSE ARE SOME OF THE HIGHEST RISK GROUPS THAT WE GET CONCERNED ABOUT. YEAH, WELL, THIS IS REALLY AMAZING FINDINGS AND GREAT RESEARCH THAT YOU AND ALL THESE OTHER PHYSICIANS AND MEDICAL EXAMINERS HAVE WORKED ON COLLECTIVELY. WE’RE GOING TO POST SOME MORE INFORMATION ON OUR WEBSITE SO YOU CAN FIND OUT AND HELP NAVIGATE YOUR JOURNEY. IF YOU IF YOU HAV

    Central Florida doctor unveils kratom research findings, potential dangers

    Orlando Health Orlando Regional Medical Center emergency medicine physician and toxicologist, Dr. Josef Thundiyil, joins WESH 2 to discuss the potential dangers of kratom.

    Updated: 10:00 AM EDT Sep 15, 2025

    Editorial Standards

    Orlando Health Orlando Regional Medical Center emergency medicine physician and toxicologist, Dr. Josef Thundiyil, joins WESH 2 to discuss the potential dangers of kratom.Click here to learn more.

    Orlando Health Orlando Regional Medical Center emergency medicine physician and toxicologist, Dr. Josef Thundiyil, joins WESH 2 to discuss the potential dangers of kratom.

    Click here to learn more.

    [ad_2]

    Source link

  • Psilocybin — the drug in ‘magic mushrooms’ — could see federal restrictions loosened

    [ad_1]

    Regulation of psilocybin — the “magic” substance in psychedelic mushrooms — has been a hot-button issue for Californians in recent years, but repeated attempts by state lawmakers to allow medical use of the substance have floundered.

    Now it seems change may come at the federal level.

    The U.S. Department of Health and Human Services is weighing a petition sent earlier this month by the Drug Enforcement Administration to review the scientific evidence and consider easing restrictions.

    Psilocybin is currently classified as a Schedule I narcotic, the most restrictive category under federal law, reserved for drugs “with a high potential for abuse” and “no currently accepted medical use.” The DEA is considering moving psilocybin into the less restrictive Schedule II tier, which includes drugs that are considered addictive or dangerous — including fentanyl and cocaine — but also have medical value.

    Past efforts to allow for therapeutic use of psilocybin have largely stalled in the face of official intransigence and lack of political will, including in California, where state lawmakers’ efforts to decriminalize psilocybin and other psychedelic substances have failed multiple times.

    Despite strict prohibition under both state and federal law, psilocybin is widely available and growing in popularity for both recreational and therapeutic purposes.

    Illegal cannabis dispensaries across Southern California openly sell actual psilocybin mushrooms, as well as dodgy chocolates and gummies that often purport to contain the substance but instead contain only synthetic versions. In recent decades, a growing body of research has found that psilocybin can be beneficial in treating mental health conditions including depression, anxiety and substance use disorder.

    The issue of psychedelic access is high on the agenda of Robert F. Kennedy Jr., Trump’s controversial and conspiracy-minded secretary of Health and Human Services. Kennedy has signaled support in the past for expanding access to some hallucinogens in medical settings for treatment of mental health disorders.

    Kennedy’s agency directed all inquiries to the DEA, which said in an email that it is “unable to comment on or confirm scheduling actions.”

    The DEA sent the psilocybin petition after a drawn-out legal battle led by Dr. Sunil Aggarwal. For about five years, Aggarwal, co-director of the Advanced Integrative Medical Science Institute in Seattle, has been seeking a means to legally obtain and administer psilocybin to ailing and aging patients for care during the final phases of their lives.

    Kathryn L. Tucker, a lawyer for Aggarwal, wrote a letter to the DEA this month that said he “continues to provide care to patients with advanced and terminal cancer who could benefit greatly from psilocybin assisted therapy, enabling them to experience a more peaceful dying process.”

    “The science supports movement to schedule II; such placement will enable access under Right to Try laws, which contemplate early access to promising new drugs for those with life-threatening conditions,” Tucker wrote.

    Aggarwal filed a lawsuit after his 2020 petition to reschedule psilocybin was denied. A federal panel dismissed the suit, but the move toward rescheduling continues now that the DEA has officially forwarded his petition to the Department of Health and Human Services.

    But some researchers and other experts caution against moving too fast to expand access.

    Dr. Steven Locke, a former Harvard Medical School psychiatry professor, wrote in an email that the question of whether psilocybin has any medical applications “remains controversial.” A past president of the American Psychosomatic Society, Locke has studied rare conditions such as Hallucinogen Persisting Perception Disorder, which cause symptoms akin to long-lasting “bad trips” in a small percentage of people who use psilocybin mushrooms and other psychedelics.

    “There is little evidence from good-quality studies to support claims for the efficacy of the use of psilocybin for the treatment of any medical disorders,” said Locke. “The reclassification should be contingent on a careful review.”

    [ad_2]

    Connor Sheets

    Source link

  • WWE Wrestler Arrested in Central Florida for Marijuana Possession – Medical Marijuana Program Connection

    WWE Wrestler Arrested in Central Florida for Marijuana Possession – Medical Marijuana Program Connection

    [ad_1]

    WWE wrestler Gionna Daddio, who wrestles under the name Liv Morgan, was arrested in Central Florida for marijuana possession after traffic stop.

    According to the Sumter County Sheriff’s Office, she was pulled over after crossing the yellow and white lines on the road in Bushnell, in Central Florida.

    In the arrest affidavit, local law enforcement initially stopped the jeep in case there was a medical incident happening, but soon claimed there was a smell of marijuana from the vehicle. Apparently, the driver admitted marijuana was in the vehicle at that point.

    After a search, a clear plastic bag with “a green leafy substance” and a vape pen with an oil-like substance inside were recovered and used to make the charges.

    She was able to bond out of the Sumter County Jail.

    Original Author Link click here to read complete story..

    [ad_2]

    MMP News Author

    Source link

  • Opinion: California didn’t ban Skittles. But it tackled a food safety problem the FDA hasn’t solved

    Opinion: California didn’t ban Skittles. But it tackled a food safety problem the FDA hasn’t solved

    [ad_1]

    Last month, Gov. Gavin Newsom signed into law California’s Food Safety Act banning four ingredients that are linked to health risks. These substances — red dye no. 3, propyl paraben, brominated vegetable oil and potassium bromate, currently found in some candies, sodas and baked goods — will not be allowed in the state’s foods starting in 2027. All four are banned from foods in the European Union (which only allows red no. 3 in candied and cocktail cherries), but, California aside, they remain perfectly legal in the U.S.

    New York is considering a similar law that would also ban a fifth substance previously included in California’s law — titanium dioxide, which is used in Skittles. That’s why the California measure got dubbed the “Skittles ban” (a name that stuck even after titanium dioxide was cut from the draft).

    California is the first state to go beyond Food and Drug Administration regulations by banning the other four additives. Should it have deferred to the FDA?

    The challenges facing the FDA make the case for state action. Sluggish and irregular safety reviews, a fast-track ingredient approval loophole that is abused by manufacturers, and a focus on acute food poisoning over long-term diet all hinder the agency’s ability to address the growing risks associated with our food supply.

    The FDA is required to review the safety of any new food additive and grant approval before it can be used. If evidence indicates that an additive is unsafe, the FDA is supposed to decline or limit its use. Three of the substances in California’s law were approved by this standard review: potassium bromate, Red Dye No. 3 and brominated vegetable oil. But the FDA is reevaluating the safety of the latter two and has proposed, though not finalized, a rule to ban brominated vegetable oil from the food supply.

    The fourth substance set to be banned in California, propyl paraben, was approved through what’s effectively a loophole in the FDA system. Ingredients classified as “generally recognized as safe” (GRAS) are exempt from the additive category and thus from careful FDA review. Congress crafted this exemption to be used infrequently, primarily to keep common ingredients like salt and spices on the market without an onerous approval process. But as food companies sought to avoid the rigorous food additive review, GRAS applications piled up.

    Without the resources to research the applications, and lacking further support from Congress, the FDA allowed manufacturers to skip the application and determine GRAS status with only a “voluntary notification process.” This means companies can choose whether to let the FDA know they believe their substance is GRAS — in which case FDA can affirm that decision — or they can self-affirm GRAS status and market the substance without ever notifying the FDA. Thousands of substances have entered the food supply this way. Even when companies voluntarily notify, as was the case for propyl paraben in 1984, the FDA does not conduct a full safety review to affirm GRAS status.

    Since GRAS notification is voluntary, the FDA does not know all the substances in our food supply. One study found that of the 4,284 GRAS determinations made as of January 2011, just 582 were cleared through the FDA’s voluntary notification process.

    Although the FDA has the authority to revoke GRAS status or an additive approval, the agency reviews the safety of greenlighted ingredients sporadically, rather than regularly — and often slowly.

    Take for example, trans fat from partially hydrogenated oils, a GRAS substance used for decades in commercial baked goods and other products. A 2004 citizen petition asked the FDA to look into the safety of these oils, but it wasn’t until 2015 that the FDA determined that they were not GRAS and banned them in food starting in 2020. By the time the FDA got around to this, New York City had already banned them in restaurants (in 2006), as had California (in 2008).

    The under-regulation of food additives is part of a larger challenge. FDA vetting focuses more on acute risks, such as food-borne illness, than on longer-term risks from diet. Of the agency’s more than $1 billion budget for its foods program, only 7% goes to nutrition and labeling, its major strategies to address diet-related disease. Yet while foodborne illness causes about 3,000 deaths per year, 1.5 million deaths in 2018 — more than half of all deaths that year — resulted from conditions linked to diet.

    But states moving to ban substances isn’t a perfect solution either. They generally don’t have the resources to conduct comprehensive safety reviews, and it would be more efficient to beef up the FDA’s infrastructure than to duplicate costly systems across states and potentially create a confusing patchwork of bans.

    We desperately need change at the federal level. The Government Accountability Office reported on flaws in the GRAS system in 2010, and the FDA has not addressed the majority of the recommendations, such as regularly reviewing the safety of GRAS substances and requiring companies to provide basic information about these substances. The FDA urgently needs additional Congressional funding to take action on food safety for all ingredients, with a particular eye toward diet-related chronic disease.

    In the meantime, states like California will have to keep taking the lead on evaluating harmful ingredients and show the federal government how it can be done.

    Emily Broad Leib is a clinical professor of law at Harvard Law School and faculty director of the school’s Food Law and Policy Clinic.

    [ad_2]

    Emily Broad Leib

    Source link